Rigel Pharmaceuticals (RIGL) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.65
- Estimate
- $0.96
- Surprise
- -32.5%
- Revenue (period 2026-09-30)
- $80.9M
- Score at report (before → after)
- 5.6 → 5.6/10
Revenue source: xbrl.
How the report landed
Rigel Pharmaceuticals (RIGL) missed the $0.96 estimate with adjusted EPS of $0.65 — a large 32.5% shortfall. TrendMatrix's engine moved from Hold (5.6/10) to Sell at 5.6/10 after the report.
Coverage in the report window
- Rigel Pharmaceuticals Raises FY2026 Sales Guidance from $285.000M-$295.000M to $290.000M-$295.000M vs $305.733M Est — benzinga, 2026-11-05
- Rigel Pharmaceuticals Q3 EPS $0.65 Misses $0.86 Estimate, Sales $80.890M Beat $80.099M Estimate — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates RIGL Sell at 5.7/10.
1 of the last 4 quarters beat the estimate; this quarter's -32.5% surprise compares with a +294.5% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.1 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: TAVALISSE
- Earnings expected to decline ~71% (cyclical peak)
- Consecutive earnings misses (3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $39.93
- Price target
- $54.81
- Stop
- $37.13
- Upside to target
- +37.3%
- Reward-to-risk
- 2.8:1
Forward estimates sit below the trailing run-rate (9.3× forward vs 2.7× trailing) — consensus expects earnings to decline from here.
Risk check: trading volume is running 1.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
RIGL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $845.7M
- P/E (fwd)
- 9.3
- P/E (ttm)
- 2.7
- 52-week range
- $24.95–$52.61
- Off 52-week high
- 24.1%
- RSI (14)
- 35
- Volume vs avg
- 1.70×
- Score today
- 5.7/10